AstraZeneca
π¬π§United Kingdom
- Country
- π¬π§United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Placebo-controlled Safety and Tolerability Study of Intravenous (IV) and Subcutaneous (SC) AZD1163 in Healthy Volunteers
- First Posted Date
- 2023-10-27
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 99
- Registration Number
- NCT06103877
- Locations
- π©πͺ
Research Site, Berlin, Germany
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
Phase 3
Recruiting
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2023-10-27
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 625
- Registration Number
- NCT06103864
- Locations
- π»π³
Research Site, Vinh, Vietnam
Harmonizing RCT-Duplicate Emulations In A Real World Replication Program (HARRP)
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: DPP4 inhibitorDrug: 2nd generation Sulfonylurea
- First Posted Date
- 2023-10-25
- Last Posted Date
- 2023-10-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 239990
- Registration Number
- NCT06099067
- Locations
- πΈπͺ
Research Site, Gothenburg, Sweden
A Prospective, Non-interventional, Observational Study of Presentation, Treatment Patterns and Outcomes in Atypical Hemolytic Uremic Syndrome Patients
Recruiting
- Conditions
- Atypical Hemolytic Uremic Syndrome(aHUS)
- First Posted Date
- 2023-10-25
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1070
- Registration Number
- NCT06099236
- Locations
- π¨π³
Research Site, Zhengzhou, China
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
Phase 3
Recruiting
- Conditions
- Unresectable Pleural Mesothelioma
- Interventions
- First Posted Date
- 2023-10-24
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 600
- Registration Number
- NCT06097728
- Locations
- π¬π§
Research Site, Taunton, United Kingdom
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AZD7503 in Japanese Healthy Participants.
Phase 1
Completed
- Conditions
- Heathy Participants
- Interventions
- Drug: PlaceboDrug: AZD7053
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 12
- Registration Number
- NCT06093542
- Locations
- π―π΅
Research Site, Sumida-ku, Japan
Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)
Phase 3
Active, not recruiting
- Conditions
- Chronic Kidney Disease With High Proteinuria
- Interventions
- First Posted Date
- 2023-10-18
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1835
- Registration Number
- NCT06087835
- Locations
- π»π³
Research Site, Ho Chi Minh, Vietnam
A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma
- First Posted Date
- 2023-10-16
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 94
- Registration Number
- NCT06084884
- Locations
- π°π·
Research Site, Seoul, Korea, Republic of
Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
Phase 3
Recruiting
- Conditions
- Locally Advanced Cervical Cancer
- Interventions
- Other: Placebo
- First Posted Date
- 2023-10-12
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 800
- Registration Number
- NCT06079671
- Locations
- πΉπ·
Research Site, Karsiyaka, Turkey
Uptake of the Childhood Live Attenuated Influenza Vaccine (LAIV) and Influenza-related Healthcare Resource Use in England During the 2012 to 2022 Flu Seasons; a Retrospective, Observational Study in the CPRD and HES Databases
Completed
- Conditions
- Influenza
- First Posted Date
- 2023-10-11
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 12775880
- Registration Number
- NCT06077045
- Locations
- π¬π§
CPRD, London, United Kingdom
Β© Copyright 2025. All Rights Reserved by MedPath